ClinicalTrials.gg
RecruitingNCT05480696FINDUpdated Nov 12, 2024

Soluble Fibre Supplementation in NAFLD

A Phase 2 interventional study of Fructo-oligosaccharide enriched inulin supplement and Maltodextrin in Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis and Hepatic Steatosis, sponsored by McMaster University. Recruiting at 1 site in Canada. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by McMaster University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
8 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 91 studies in Non-alcoholic Fatty Liver Disease with a site in Canada — 14 open to participants now, 22 under way, 9 of them phase 3. Non-alcoholic Fatty Liver Disease · Canada.

Planned enrollment
57th of 77
60 · median 164
Started
2022
with 3 others
Phase 2
38 of 91
1 open now
Primary completion
2027-03
later than 11 of 21 live
Registered
74th of 91
by date

Among the 91 studies in Non-alcoholic Fatty Liver Disease with a site in Canada, this one is the 57th largest by planned enrollment of the 77 interventional ones that give a count, is one of 4 that started in 2022, is one of 38 in phase 2, reaches primary completion later than 11 of the 21 other live ones, and was the 74th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

14 of the 91 studies in Non-alcoholic Fatty Liver Disease with a site in Canada are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 8 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Non-alcoholic Fatty Liver Disease with a site in Canada, or all of them as a file.
02

Study summary

The FIND study will look at the effect of a nutritional mixed fibre supplement, oligofructose and inulin (OF+INU), on children with non-alcoholic fatty liver disease. In this randomized, double- blind controlled trial, subjects will be given a supplement, in the form of oral pills, and will have bloodwork performed, their diets analyzed, and liver fat measured at several timepoints. Liver fat will be measured by using a specialized MRI device located at St. Joseph's Hospital. Subjects will be recruited from the Children's Exercise and Nutrition Clinic.

Read the detailed description

The FIND (Fibre in Non-Alcoholic Fatty Liver Disease) study will be a single-centre, randomized, double-blind placebo-controlled trial comparing the effects of 6 months of mixed oligofructose and inulin (OF+INU) supplementation vs placebo on hepatic fat content, hepatic stiffness, metabolic outcomes, and body composition in children ages 8-17 years old.

Assessments such as MRI measurements of hepatic fat and hepatic stiffness, anthropometry and pubertal status questionnaires, and other investigations such as body composition via dual energy X-ray absorptiometry (DXA), fasting lipids, liver enzymes, blood glucose and oral-glucose tolerance (OGTT) tests will be performed; and randomization will be conducted via REDCap software.

Eighty participants will be enrolled for baseline evaluation in order to randomize sixty participants for the intervention phase (i.e. thirty participants per study group). Participants will consume one packet (4g) of OF+INU or placebo (Maltodextrin) daily. If tolerated, this will increase to one packet twice daily. Several strategies will be implemented to increase compliance, including text message reminders (daily for first week, then weekly), study calls to assess compliance and tolerability, and check-ins with participants at each clinic visit. These interactions will allow the study team to assess challenges and offer prompt support. Compliance will be assessed at each study visit by counting empty and unused sachets. Treatment with OF+INU or placebo will occur for 6 months, with study visits being conducted at baseline evaluation, 3 months and 6 months

03

Conditions studied

  • Non-Alcoholic Fatty Liver Disease
  • Non Alcoholic Steatohepatitis
  • Hepatic Steatosis
04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children ages 8-17 years
  • Diagnosed with obesity ( ≥2 standard deviations above WHO reference median)
  • Enrolled in GHWM Clinic
  • Clinical evidence of NAFLD (elevation of , greater than 2x upper-limit-of-normal () [ALT>80 IU/L for 8-17 years of age], and hepatic steatosis measured as part of clinic enrolment).

Exclusion criteria

Exclusion Criteria:

  • Type 1, Type 2 diabetes mellitus (T1DM, T2DM)
  • to having MRI (claustrophobia, metal implant, recent tattoo, weight > 300lbs)
  • Concomitant use of other fibre supplements
  • Medications known to affect hepatic fat content, taken within the past year (i.e., , anabolic steroids, tetracycline, anticonvulsants, antipsychotics, glucose- lowering medications)
  • Presence of another known cause of liver disease
  • Known allergy or to OF-INU supplementation
  • Self-reported alcohol intake >7 drinks/week or 3 drinks/day
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Oligofructose Inulin Supplementation

    The intervention group will receive a daily fibre supplementation of (fructo-oligosaccharide enriched inulin, 4g twice daily; Orafti®Synergy1, BENEO), a tasteless white powder contained within a tear-able, partitioned 4g sachet, sprinkled and dissolved in 125 mL of water.

    Dietary Supplement: Fructo-oligosaccharide enriched inulin supplement

  • Sham comparator
    Maltodextrin Supplementation

    The control group will receive a daily supplementation of carbohydrate placebo (isocaloric maltodextrin), identical in colour, packaging, preparation, and dose (4g, twice daily; C\*Dry MD™,Cargill).

    Other: Maltodextrin

Interventions

  • Dietary supplementFructo-oligosaccharide enriched inulin supplement

    Experiment

  • OtherMaltodextrin

    Placebo.

06

What researchers measure

Primary outcomes

  1. Change in hepatic fat content.

    Hepatic fat content will be measured via MRI at baseline and 6-months using standard techniques, optimized for accuracy, precision and reproducibility of proton density fat fraction (PDFF) quantification.

    Time frame: Six months

Secondary outcomes

  1. Change in hepatic stiffness.

    Hepatic stiffness, a measure of hepatic fibrosis, will be measured via MRI using standard techniques.

    Time frame: Six months

  2. Change in glycemic control, or insulin resistance.

    Measured using plasma glucose (fasting and + 2 hours following oral glucose load) and HbA1c from a 2-hour OGTT (1.75g/kg, up to maximum of 75g glucose administered).

    Time frame: Six months

  3. Change in liver enzymes (ALT, AST, GGT, or ALP)

    Liver enzymes will be measured using Abbott ARCHITECT Systems

    Time frame: Six months

  4. Change in body fat percentage

    Body fat will be measured using a DXA scanner, by research team members previously trained in DXA measurement.

    Time frame: Six months

  5. Change in weight

    Weight will be measured using an electronic platform scale.

    Time frame: Six months

  6. Change in height

    Height will be measured using a wall mounted stadiometer.

    Time frame: Six months

  7. Change in BMI

    BMI will be calculated mathematically from other outcomes such as height and weight.

    Time frame: Six months

Other outcomes

  1. Changes in molecular profiling of gut microbiome

    Profiling of the gut microbiome will be measured from collected stool samples

    Time frame: Six months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Mar 2027, 54 months after the start.

Of 53 non-industry phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 56. This study's planned 54 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2022
First posted
Jul 29, 2022
StartActual
Sep 9, 2022
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05480696
Responsible party
Sponsor
First posted
Jul 29, 2022
Start date
Sep 9, 2022
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 12, 2024

Study contacts

Paige AL Cheveldayoff, BSC
Contact
cheveldp@mcmaster.ca
3063611281
Nikhil Pai, MD
Contact
pain@mcmaster.ca
2892082457
Nikhil Pai, MD
principal investigator · McMaster University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion